To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


CURE Staff
One of our valued community members, Jen Sotham, passed away on Nov. 9. Jen was diagnosed with metastatic melanoma in 2014, but that did not prevent her from living out her dreams and having her voice heard through film, blogging, a TED talk and contributing to CURE® — both in print and on the web.
Lisa Astor
Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) improved response rates in patients with melanoma, but not without some severe side effects.
Barbara Tako
Two-time cancer survivor struggles with a different loss than cancer this holiday season.
Barbara Tako
Are you trying to get ready for the holidays in addition to being newly diagnosed with cancer, receiving active treatment or coping with survivorship? It’s not an easy task.
Barbara Tako
A two-time cancer survivor shares strategies that have helped her over the years with healthy eating habits and movement.
Danielle Bucco
In an interview with CURE, Postow, a medical oncologist specializing in melanoma at Memorial Sloan Kettering Cancer Center, discussed the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.
Katie Kosko
Nearly a third of tanning salons surveyed were not compliant with their state laws.
An immunotherapy finally gives doctors an approved weapon to fight Merkel cell carcinoma, a rare and still mysterious skin cancer.
Barbara Tako
It isn't always so "normal," is it?
Jason Harris
The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the adjuvant treatment of patients who have stage 3 melanoma and a BRAF V600 mutation, after they have already had a complete resection.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable